Literature DB >> 18669449

Challenges and pitfalls of combining targeted agents in phase I studies.

Stephen A Cannistra.   

Abstract

Mesh：

Substances：

Year:  2008        PMID： 18669449     DOI： 10.1200/JCO.2008.17.2676

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  15 in total

Review 1.  Current challenges for the early clinical development of anticancer drugs in the era of molecularly targeted agents.

Authors:  Christophe Le Tourneau; Véronique Diéras; Patricia Tresca; Wulfran Cacheux; Xavier Paoletti
Journal:  Target Oncol       Date:  2010-04-02       Impact factor: 4.493

Review 2.  Envisioning the future of early anticancer drug development.

Authors:  Timothy A Yap; Shahneen K Sandhu; Paul Workman; Johann S de Bono
Journal:  Nat Rev Cancer       Date:  2010-06-10       Impact factor: 60.716

Review 3.  The changing landscape of phase I trials in oncology.

Authors:  Kit Man Wong; Anna Capasso; S Gail Eckhardt
Journal:  Nat Rev Clin Oncol       Date:  2015-11-10       Impact factor: 66.675

4.  Bevacizumab in ovarian cancer: unanswered questions.

Authors:  Franco Muggia
Journal:  Drugs       Date:  2012-05-07       Impact factor: 9.546

5.  A Phase I/II adaptive design to determine the optimal treatment regimen from a set of combination immunotherapies in high-risk melanoma.

Authors:  Nolan A Wages; Craig L Slingluff; Gina R Petroni
Journal:  Contemp Clin Trials       Date:  2015-01-29       Impact factor: 2.226

6.  Dose-finding designs for trials of molecularly targeted agents and immunotherapies.

Authors:  Cody Chiuzan; Jonathan Shtaynberger; Gulam A Manji; Jimmy K Duong; Gary K Schwartz; Anastasia Ivanova; Shing M Lee
Journal:  J Biopharm Stat       Date:  2017-02-06       Impact factor: 1.051

Review 7.  Targeting angiogenesis: progress with anti-VEGF treatment with large molecules.

Authors:  Axel Grothey; Evanthia Galanis
Journal:  Nat Rev Clin Oncol       Date:  2009-07-28       Impact factor: 66.675

8.  Modeling NSCLC progression: recent advances and opportunities available.

Authors:  Ahmed Abbas Suleiman; Lucia Nogova; Uwe Fuhr
Journal:  AAPS J       Date:  2013-02-13       Impact factor: 4.009

9.  Pharmacokinetic/Pharmacodynamic modeling of abexinostat-induced thrombocytopenia across different patient populations: application for the determination of the maximum tolerated doses in both lymphoma and solid tumour patients.

Authors:  Quentin Chalret du Rieu; Sylvain Fouliard; Mélanie White-Koning; Ioana Kloos; Etienne Chatelut; Marylore Chenel
Journal:  Invest New Drugs       Date:  2014-05-31       Impact factor: 3.850

10.  Clinical benefit in Phase-I trials of novel molecularly targeted agents: does dose matter?

Authors:  S Postel-Vinay; H-T Arkenau; D Olmos; J Ang; J Barriuso; S Ashley; U Banerji; J De-Bono; I Judson; S Kaye
Journal:  Br J Cancer       Date:  2009-05-05       Impact factor: 7.640
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.